BELFOR, the Global Market Leader in Damage Restoration, Expands its Geographical Coverage With SSG Group, Scandinavia
22.6.2022 17:59:00 EEST | Business Wire | Press release
BELFOR, the world’s leading provider of disaster recovery services, and SSG, the Scandinavian market leader in damage restoration services, have joined forces to strengthen their customer service in Denmark, Sweden and Norway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005595/en/
BELFOR, the Global Market Leader in Damage Restoration, Expands its Geographical Coverage With SSG Group, Scandinavia (Graphic: Business Wire)
BELFOR, now with more than 12.500 employees in 500+ locations throughout the world, covers the whole value chain in disaster recovery - from damage assessment, first mitigation measures, restoration to reconstruction services for small, large and technically complex losses.
SSG Group provides a broad service offering focussing on damage prevention, damage restoration, repair and reconstruction services with 980 employees in 57 locations in Denmark, Sweden and Norway.
“With SSG, we will grow our skilled and experienced teams with great people, increase our service capability and optimize our response times for our national and international clients”, explains Elvir Kolak, CEO of BELFOR Europe.
Carsten Fensholt, CEO of SSG Group, adds: "This transaction means a tremendous boost for our organizations in Denmark, Norway and Sweden as it adds the technical competence of BELFOR to our service portfolio and provides new development opportunities for our employees.”
BELFOR will now be the number 1 restoration company in Denmark supported by 650 people. This acquisition represents a significant step forward in terms of BELFOR’s geographical expansion into Scandinavia, which has started in Denmark in 2016 with the acquisition of Rosva followed by Rolund in 2021.
"We are happy to welcome SSG to our BELFOR family and are excited to support their future growth. SSG employs wonderful people with a great customer focus - a perfect match! We are proud to have them on board. Our growth plans are ambitious and we are looking for more great companies to join the BELFOR family - in Scandinavia as well as across Europe”, concludes Sheldon Yellen, the global CEO of BELFOR.
ABOUT BELFOR
BELFOR is the world's leading provider of disaster recovery services. BELFOR has over 40 years of experience, covering the whole value chain from damage assessment, restoration and renovation services. This makes us a preferred partner for the insurance industry as well as for commercial and private clients.
With SSG, BELFOR will have more than 12,500 employees and 500+ locations in 57 countries. Ready to help customers on small, large and technically complex losses 24/7, 365 days a year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005595/en/
Contact information
Cornelia Meyer von Bremen
Tel: +49 (0) 203 - 7 56 40-300
cornelia.meyervonbremen@belfor.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom